ORGO Q2 revenue collapses 57% to $43.8M; net loss widens to -$96.3M on tax valuation allowance

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~2 min read

Key Changes

• high

  Net loss widened 925% to $96.3M (diluted EPS -$0.77) while operating loss widened 305% to $51.0M — the bottom-line deterioration came from a $47.8M income tax expense (vs. $2.4M benefit prior year) as the company established a full valuation allowance on deferred tax assets, concluding future taxable income is unlikely.

  MD&A: Income Tax / Notes: Deferred Tax Assets verify on EDGAR →
• high

  Revenue fell 57% to $43.8M (from $101.0M) as Advanced Wound Care revenue dropped 61% to $36.1M, driven by "clinician confusion and material disruption" from the December 2025 LCD withdrawal and CMS discarded-product comments; management discloses the decline is continuing into Q3 2026.

  MD&A: Revenue verify on EDGAR →
• high

  Gross margin compressed to 45% (from 73%) as gross profit fell 74% to $19.1M, driven by "volume and pricing related impacts of the Medicare reimbursement changes and product mixes."

  MD&A: Gross Profit verify on EDGAR →